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Introduction 
Chorea  is  a  hyperkinetic  movement  disorder  characterised  by  excessive  spontaneous 
movements that are irregularly timed, randomly distributed and abrupt. It ranges in severity 
from  restlessness  with  mild,  intermittent  exaggeration  of  gesture  and  expression,  fidgety 
movements of the hands (seen online video) and unstable dance-like gait to a continuous 
flowing of disabling and violent movements.  In this article we discuss the causes of chorea 
and an approach to its assessment. 
A brief history of chorea 
The term chorea is from the Greek koreia () meaning a dance. The word was first 
used medically by the alchemist Paracelsus (1493-1541) to describe Chorea Sancti Viti (St 
Vitus’ dance), which was probably an epidemic form of hysterical chorea occurring in the 
context of religious or superstitious fervour.
1 Thomas Sydenham (1624-1689), studying St 
Vitus’ dance, identified a form of childhood chorea that now bears his name.  
One year after obtaining his medical qualification, George Huntington (1850-1916) in 1872 
described a hereditary form of chorea “spoken of by those in whose veins the seeds of the 
disease are known to exist, with a kind of horror”, with onset in adult life and associated with 
cognitive  and  psychiatric  manifestations.  Huntington’s  disease  (HD)  is  the  commonest 
hereditary cause of chorea, and the mutation causing it was identified in 1993 as a result of 
an international collaborative initiative.
2 
Differential diagnosis 
The major causes of chorea can be simply divided into inherited and acquired (Table 1).  
Table 1 Major inherited and acquired causes of chorea 
 
Inherited causes 
  Huntington’s disease* Wild/Tabrizi  3 
  Neuroacanthocytosis 
  Macleod syndrome 
  Dentatorubro-pallidoluysian atrophy (DRPLA) 
  Benign hereditary chorea 
  Spinocerebellar ataxia (SCA) types 1, 2, 3 and 17 
  Mitochondrial disorders 
  Inherited prion disease 
  Huntington’s disease-like 2 (HDL2) 
  Wilson’s disease 
  Friedreich’s ataxia 
  Neurodegeneration with brain iron accumulation (NBIA) 
  Ataxia telangiectasia 
  Neuroferritinopathy 
  Lysosomal storage disorders 
  Amino acid disorders 
  Tuberose sclerosis 
 
 
Acquired causes 
  Focal striatal pathology 
o  Stroke 
o  Space-occupying lesions 
  Drug-induced (see Table 3) 
  Chorea gravidarum 
  Thyrotoxicosis 
  Systemic lupus erythematosus (SLE) / Antiphospholipid syndrome (APLS) 
  Post-infective 
o  Sydenham’s chorea (group A streptococcal infection) 
o  Paediatric autoimmune disorders associated with streptococcal infections (PANDAS) 
o  Herpes simplex encephalitis 
  Polycythaemia rubra vera 
  Infective 
o  AIDS 
o  Variant Creutzfeld-Jakob disease (vCJD) 
 
* the commonest cause of inherited chorea—the remainder of these disorders are rare. 
Inherited causes 
Huntington’s disease 
Huntington’s disease (HD) is a progressive autosomal dominant neurodegenerative disorder 
and the commonest inherited cause of chorea. Onset is usually in adult life with a mean age 
of about 40 years, although juvenile and  elderly onset  are  well described.  It  progresses 
inexorably, with death occurring 15-20 years from the time of onset. Prevalence is 4-10 per 
100,000 in Western European populations, but HD has been described throughout the world. Wild/Tabrizi  4 
Genetics and pathology 
The gene defect associated with HD is a CAG repeat expansion, encoding polyglutamine 
repeats within the huntingtin protein.
2 The CAG repeat ranges between 10 and 29 copies on 
normal chromosomes, and is expanded to a range of 36-121 on HD chromosomes.  CAG 
repeats above 40 are fully penetrant, with a borderline range between 36 and 39 repeats 
associated with reduced penetrance.
3  
CAG  repeat  lengths  tend  to  increase  down  generations,  particularly  when  transmitted 
through  the  paternal  lineage.
4  This  underlies  the  phenomenon  of  anticipation—the 
increasing  severity  of  HD  during  intergenerational  transmission.  There  is  a  correlation 
between CAG repeat size and age of onset—the larger the repeat, the earlier the disease 
onset.
5 Most individuals with greater than 50 repeats develop the disease before the age of 
30.
6 However, CAG repeat length accounts for only 50-70% of variation of age of onset, and 
does not predict the clinical phenotype nor the severity of disease progression.
7 
Motor features 
HD can produce a wide range of phenotypic presentations and the signs and symptoms 
change as it progresses.
8  
The  onset  of  HD  is  often  difficult  to  discern  clearly  and  many  patients  have  psychiatric 
problems  or  cognitive  symptoms  prior  to  the  appearance  of  any  motor  problems.  The 
definitive  diagnosis  of  HD  is  usually  made  when  motor  abnormalities  are  noted  on 
examination. Minor motor abnormalities seen early in the disease are general restlessness, 
abnormal eye movements, hyperreflexia and fidgety movements of fingers, hands and toes 
during  stress  or  when  walking.  Oculomotor  abnormalities  are  a  cardinal  feature  of  the 
disease  and  often  the  earliest  motor  sign.  Saccadic  abnormalities  are  characteristic, 
including delayed initiation and slowing and inability to suppress glances at novel stimuli. As 
the  disease  progresses,  blinking  and  head  thrusting  are  seen  during  saccade  initiation. 
Later, impaired pursuit and gaze impersistence are seen.
9  Patients develop more obvious Wild/Tabrizi  5 
extrapyramidal signs; chorea is seen in 90% of adult-onset patients with varying degrees of 
dystonia, parkinsonism and bradykinesia. A key motor abnormality in HD is impairment of 
voluntary motor function with clumsiness, motor impersistence, disturbances in fine motor 
control and motor speed. Gait disturbance is common with impairment of postural reflexes 
making patients more prone to falling. Dysarthria and dysphagia are common. 
Cognitive features 
Cognitive abnormalities are a near-universal feature and present early in the course of HD 
but vary greatly in severity.  Executive function is most impaired with poor planning and 
judgement,  impulsive  behaviour,  disorganisation  and  difficulty  coping  with  multiple  tasks. 
Many  patients  exhibit  psychomotor  slowing  with  apathy,  lack  of  self-care  and  loss  of 
initiative.
10 
Psychiatric features 
Psychiatric symptoms are common, particularly depression and anxiety.
10 Irritability is also 
common and some patients become aggressive. Obsessions and compulsions can make life 
difficult for carers. Psychosis is well-recognised but rare. Suicide is much more common in 
HD in the general population.
11 Psychiatric symptoms should be actively managed with the 
same drugs used in standard psychiatric practice.
12  
Juvenile HD 
Juvenile HD cases have more severe disease with a shorter life expectancy.  The akinetic-
rigid form of the disease (Westphal variant) is more common in juvenile HD cases: patients 
have  little  chorea  and  are  rigid,  Parkinsonian  and  dystonic.  Akinetic-rigid  forms  of  the 
disease  are  rare  in  older  age  groups.  Juvenile  HD  patients  have  a  higher  incidence  of 
seizures than adult-onset patients.
8 Wild/Tabrizi  6 
Huntington’s disease phenocopies 
The  combination  of  chorea,  cognitive  impairment,  psychiatric  abnormalities  and  an 
autosomal  dominant  family  history  was  diagnostic  of  HD  until  the  advent  of  diagnostic 
genetic testing. 1% of suspected HD cases test negative for the CAG expansion and are 
known as HD phenocopies. The major genetic HD phenocopy syndromes are listed in Table 
2. A diagnosis is made in only 2% of HD phenocopy patients.
13 
Table 2 Genetic causes of HD phenocopy syndromes 
Condition  Cause 
HDL1  Octapeptide insertion in gene encoding prion protein  
HDL2  Triplet repeat expansion in gene encoding junctophilin-3  
HDL3  Causative mutation unidentified 
SCA17  Triplet  repeat  expansion  in  gene  encoding  TATA-box  binding 
protein  
Inherited prion disease  Mutations in gene encoding prion protein 
SCA1  Triplet repeat expansion in gene encoding ataxin-1 
SCA3  Triplet repeat expansion in gene encoding ataxin-3 
DRPLA  Triplet repeat expansion in gene encoding atrophin-1 
Chorea-acanthocytosis  Mutation in gene encoding chorein 
Neuroferritinopathy  Mutations in gene encoding ferritin light-chain 
 
HDL1 is a rare inherited prion disorder. HDL2 is caused by a CAG/CTG expansion in the 
gene encoding junctophilin-3 and is generally rare, except in individuals of African ancestry 
where it is almost as common as HD.
14 
Spinocerebellar ataxias 
The spinocerebellar ataxias (SCAs) are a group of autosomal dominant neurodegenerative 
conditions,  causing  cerebellar  ataxia  and  a  spectrum  of  associated  features.  SCAs  may 
cause hyperkinetic movement disorders including chorea. SCA17, causes cognitive decline 
and neuropsychiatric features
15 and is the commonest cause of HD phenocopy syndromes 
in European populations.
13 Dentatorubral-pallidoluysian atrophy (DRPLA) causes ataxia, 
chorea and cognitive impairment but is usually distinguished from HD by the presence of 
myoclonic epilepsy.
15 Wild/Tabrizi  7 
Wilson’s disease 
Wilson’s  disease  is  an  autosomal  recessive  disorder  of  copper  metabolism  caused  by 
mutations in ATP7B. Its neurological manifestations most commonly comprise an akinetic-
rigid  syndrome  with  dysarthria,  dystonia,  tremor  and  ataxia.  16%  of  patients  experience 
chorea. Kayser-Fleischer rings in the cornea and MRI abnormalities are seen in almost all 
patients  with  neurological  signs  and  the  diagnosis  is  confirmed  by  low  serum 
caeruloplasmin, high urinary copper levels and high copper concentration on liver biopsy.
16 
Mitochondrial disease 
Mutations in DNA encoding mitochondrial proteins are increasingly recognised as causes of 
neurological disease. Myoclonus and dystonia are the most common movement disorder 
seen in mitochondrial disease but chorea can occur.
17 
Iron accumulation disorders 
Neuroferritinopathy is a rare autosomal dominant disorder caused by mutations in FTL. It 
results  in  abnormal  iron  accumulation  in  the  basal  ganglia  causing  chorea  and  other 
movement disorders as well as cognitive impairment.
18 Neurodegeneration with brain iron 
accumulation (NBIA), caused by mutations in PANK2, is an autosomal recessive cause of 
chorea.
19 MRI imaging is invariably abnormal in these disorders.
18,19 
Neuroacanthocytosis 
Neuroacanthocytosis refers to a group of neurological disorders in which acanthocytes are 
seen  on  peripheral  blood  films.  Chorea-acanthocytosis  is  a  rare  autosomal  recessive 
disorder  associated  with  mutations  in  CHAC.
20  It  causes  a  progressive,  adult-onset 
syndrome encompassing movement disorder, psychiatric and cognitive changes that may 
mimic  HD  (see  Table  2).  The  movement  disorder  includes  chorea,  dystonia  and  tics. 
Orofacial dystonia is characteristic, with tongue protrusion and biting of the tongue and lips. 
Psychiatric and cognitive features are similar to HD. Unlike HD, seizures are seen in 50% of 
patients,  and  there  is  commonly  distal  amyotrophy  or  neuropathy  with  elevated  serum Wild/Tabrizi  8 
creatine kinase.
21 Macleod syndrome is an X-linked recessive disorder linked to mutations 
in XK. Limb chorea is and facial tics are common but dystonia is less prominent than in 
chorea-acanthocytosis.  Axonal  neuropathy,  subcortical  dementia  and  psychiatric  features 
are features. Cardiomyopathy and haemolytic anaemia are common.
21 
Benign hereditary chorea 
Benign hereditary chorea (BHC) is a dominantly inherited disorder caused by mutations in 
TITF1.  It  is  usually  young-onset  with  very  slowly  progressive  chorea  without  cognitive 
decline or other neurological features.
22 However, BHC may include atypical clinical features 
such as dystonia, myoclonus, dysarthria, gait disturbances and intellectual impairment.
23 
Friedreich’s ataxia 
Friedreich’s ataxia, which is autosomal recessive, is usually characterised by progressive 
cerebellar  ataxia,  peripheral  neuropathy,  cardiac  abnormalities  and  diabetes  mellitus. 
Chorea is a rare manifestation.
24 
Acquired causes of chorea 
A cause is identified in most cases of acquired chorea. In a recent Italian case series, the 
commonest  causes  were  stroke,  drug-induced,  AIDS-related  and  metabolic 
(hyperglycaemia, hyponatraemia and hypoxia),
25 though there is regional variation: in Brazil, 
for  example,  Sydenham’s  chorea  is  responsible  for  the  majority  of  cases  of  acquired 
chorea.
26 
Vascular chorea 
Vascular  lesions  of  the  basal  ganglia  typically  cause  rapid-onset  chorea  affecting  the 
contralateral limbs. Stroke-induced chorea often remits spontaneously.
27 
Post-infective autoimmune CNS disorders 
Sydenham’s  chorea  and  PANDAS  (paediatric  autoimmune  neuropsychiatric  disorders 
associated  with  streptococcal  infection)  present  with  chorea  and  neuropsychiatric Wild/Tabrizi  9 
manifestations. Sydenham’s chorea is one of the major manifestations of rheumatic fever. It 
occurs  in  children,  mainly  girls,  and  is  now  rare  in  the  developed  world.  Chorea,  tics, 
behavioural disturbance and obsessive-compulsive symptoms are common. It is self-limiting 
and usually resolves within 6 months, though about 20% of cases are recurrent. Anti-basal 
ganglia  antibodies  can  be  detected.
28  The  disease  mechanism  is  thought  to  be  cross-
reaction between anti-streptococcal antibodies and basal ganglia neurons. Treatment with 
steroids,  intravenous  immunoglobulin  and  plasmapheresis  may  be  effective  in  refractory 
cases.
29,30  Chorea  with  anti-basal ganglia  antibodies  has  been  reported following  herpes 
simplex encephalitis.
31 
Drug-induced chorea 
Neuroleptic-induced  tardive  dyskinesia  and  levodopa-induced  hyperkinesia  are  the 
commonest medication causes of chorea in neurological practice. Many drugs are known to 
cause chorea; the commonest causes are shown in Table 3. Most such reactions remit on 
ceasing  the  offending  medication  but  some  (notably  tardive  dyskinesia)  may  persist  for 
months or years.
32 Chorea induced by the oral contraceptive pill (OCP) is linked to childhood 
Sydenham’s chorea and may be mediated by anti-basal ganglia antibodies.
33 
Table 3. Medications most commonly causing chorea 
  Neuroleptics 
  Levodopa 
  Anticonvulsants 
o  Phenytoin 
o  Carbamazepine 
o  Valproate 
o  Gabapentin 
  CNS stimulants 
o  Amphetamines 
o  Cocaine 
o  Methylphenidate 
  Benzodiazepines 
  Oestrogen-containing OCP 
  Lithium 
  Dopamine agonists Wild/Tabrizi  10 
Other acquired causes 
4% of patients with systemic lupus erythematosus (SLE) develop chorea. It usually occurs 
early in the disease and may precede other findings by several years. Patients with SLE who 
produce antiphospholipid antibodies are more likely to develop chorea. The antiphospholipid 
syndrome—the  association  of  such  antibodies  and  thrombosis,  miscarriage  and 
thrombocytopenia—may occur independently of SLE and is a cause of chorea in its own 
right.
34  Chorea  is  a rare feature  of  thyrotoxicosis. It  relates  directly  to  elevated  thyroid 
hormone levels and usually resolves once the euthyroid state is restored.
35Hemichorea is 
the movement disorder most commonly associated with AIDS, and can be the presenting 
feature. In one case series, 5/51 cases of acquired chorea were AIDS-associated.
25 Chorea 
in AIDS is usually due to a striatal toxoplasmic abscess. Rarer causes of chorea in AIDS 
include  cryptococcus,  progressive  multifocal  leukoencephalopathy,  HIV  encephalitis  and 
drug treatment.
36Chorea gravidarum usually presents in the first trimester of pregnancy and 
is self-limiting. Previous rheumatic fever, anti-basal ganglia antibodies and antiphospholipid 
syndrome  are  risk  factors.
37Chorea  is  a  rare  feature  of  polycythaemia  rubra  vera,  a 
myeloproliferativea  disorder  causing  increased  red  cell  mass  that  commonly  produces 
neurological manifestations.
38 Chorea is not seen in secondary polycythaemia, suggesting 
that it relates to an underlying molecular abnormality.
39 
Assessment 
Assessment  of  the  choreic  patient  depends  on  directed  history,  examination  and 
investigations (figure 1).  Wild/Tabrizi  11 
HISTORY
Description
of chorea
Associated
neurological
features
Cognitive history
Psychiatric history
Family history
Drug history
Medical history
EXAMINATION
Confirm chorea
Other
movement 
disorders
Eye movements
Peripheral 
neuropathy
 Onset
 Progression
 Patient insight
 Seizures
 Falls
 Myoclonus
 Sleep disturbance
 Dysphagia
 Dysarthria
 Rash
 Metabolic disturbance
 HIV risk factors
 Detailed
 3+ generation
 Consanguinity
 Neuroleptics
 Levo-dopa
 Anticonvulsants
 Irritability
 Depression
 Anxiety
 From informant
 Poor organisation
 Impaired 
concentration
 Severity
 Distribution
 Symmetry
 Ataxia
 Parkinsonism
 Dystonia
 Moclonus
 Nystagmus
 Broken pursuits
 Delayed saccade 
initiation
 Slow saccades
Amyotrophy
 Wild/Tabrizi  12 
Figure 1. Clinical assessment of the choreic patient 
History 
First, obtain the patient’s description of the chorea. A patient with mild chorea may not 
appear choreic during observation, so it is important to ask about fidgetiness or restlessness. 
Cognitive impairment may affect insight: patients with HD are notoriously often unaware of 
their chorea and may deny the existence of obvious movements.
8 A description by a relative 
or carer is often helpful. Impaired insight makes eliciting the history challenging but can be a 
useful pointer to the cause of chorea. Most inherited causes of chorea are associated with 
gradual onset and progression. HD and the other hereditary causes of chorea fall into this 
category. Rapid onset is more associated with acquired causes, particularly vascular and 
drug-induced chorea. 
Associated neurological features may direct you to the diagnosis. Falls may suggest the 
presence  of  another  disorder  such  as  pyramidal  tract  dysfunction,  ataxia  or  peripheral 
neuropathy. Seizures suggest a diagnosis of DRPLA. Myoclonus is associated with inherited 
and  acquired  prion  disease.  Sleep  disturbance,  dysarthria  and  dysphagia  are  common 
features of HD. 
The  past  medical  history  may  suggest  a  cause  for  the  chorea,  such  as  the  rash  and 
arthralgia of SLE or symptoms of thyrotoxicosis. It is important to ask about risk factors for 
HIV  transmission.  Recent  streptococcal  infection  or  history  of  rheumatic  fever  or 
Sydenham’s chorea is clearly suggestive. 
A detailed family history is essential in the assessment of any choreic patient, but there are 
several  pitfalls.  A  3-generation  pedigree  (i.e.  including  the  subject’s  parents  and 
grandparents) is the minimum suggested level of enquiry. Autosomal dominant disorders are 
usually  clear  from  their  representation  in  each  generation.  Mitochondrial  disorders  are 
inherited  from  the  mother  and  cannot  be  passed  on  by  males.  Autosomal  recessive 
inheritance can be difficult to identify, because there may be no affected relatives within Wild/Tabrizi  13 
several  generations.  Specific  enquiry  about  consanguineous  partnerships,  or  a  distant 
relative with a similar condition can raise suspicion here. 
Genetic  aetiology  can  never  be  excluded  with  complete  confidence  because  of  the 
possibilities  of  non-paternity  and  new  mutations.  Conversely,  the  presence  of  a  positive 
family history does not exclude an alternative acquired cause. It is therefore important to 
remain open-minded and, if in doubt, pursue both possibilities. Genetic testing should always 
be preceded by proper genetic counselling as discussed below. 
A detailed drug history may reveal possible causes of chorea (see Table 3) but may also 
be  a  confounding  factor,  for  instance  in  a  neuroleptic-treated  patient  whose  psychiatric 
disturbance is due to HD. Establishing the exact sequence of symptoms and drug treatments 
is essential. 
A  cognitive  history  should  be  obtained  from  both  the  patient  and  a  friend  or  carer. 
Particular attention should be paid to the subtle features of frontal-subcortical dementia such 
as poor organisation and impaired concentration. 
A psychiatric history may reveal depression, anxiety or irritability common to HD and its 
phenocopies. 
Examination 
A  neurological  and  general  medical  examination  is  essential  in  the  assessment  of  any 
patient with new symptoms. Figure 1 highlights key examination findings and Table 5 lists 
the associations of abnormal findings in the differential diagnosis of chorea. 
The first priority is to confirm the presence of chorea. Chorea is usually seen in general 
observation before formal examination. It is often best noticed out of the corner of the eye—
for instance, you may observe a fidgeting foot while the patient is speaking—and may be 
enhanced by distraction. The first movement abnormality in Huntington’s disease is often Wild/Tabrizi  14 
subtle  flicking  of  the  fingertips  while  walking  (see  online  video).  Chorea  should  be 
distinguished from the list of related disorders in Table 4.  
Table 4. Chorea and related hyperkinetic movement disorders 
Disorder  Nature of involuntary movement   
Chorea  Irregular, seemingly random, semi-directed movements 
Athetosis  Continuous writhing movements 
Ballismus  Sudden, vigorous, forceful movements usually involving a whole limb 
Dystonia  Sustained contraction  of opposing muscle groups causing twisting movements and 
abnormal postures 
Myoclonus  Sudden, brief, shock-like movements caused by muscular contraction or inhibition 
 
In most cases chorea is bilateral, and symmetrical. Hemichorea is usually due to vascular 
causes or contralateral basal ganglia lesions (including AIDS-associated chorea). 
The presence of other movement disorders is of importance. Cerebellar ataxia is unusual in 
adult-onset  HD  and  suggests  an  alternative  diagnosis  such  as  spinocerebellar  ataxia, 
Friedreich’s  ataxia  or  choreo-acanthocytosis.  Dystonia  and  parkinsonism  are  present  in 
moderate/advanced  HD,  juvenile  HD  and  the  Westphal  variant.  Orolingual  dystonia  is 
relatively specific to chorea-acanthocytosis. 
Table 5. Abnormal examination findings in the differential diagnosis of chorea 
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HD        ●  ●  ●  ●
a  ●
a      ● 
Chorea-acanthocytosis  ●  ●  ●      ●        ●  ● 
Macleod’s syndrome  ●  ●  ●      ●          ● 
Friedreich’s ataxia  ●  ●                   
Mitochondrial disease  ●  ●    ●        ●  ●     
Ataxia telangiectasia  ●  ●    ●               
Spinocerebellar ataxias  ●
b  ●    ●              ●
c 
DRPLA    ●                   
Prion disease    ●              ●     Wild/Tabrizi  15 
Wilson's        ●    ●  ●  ●      ● 
NBIA              ●  ●       
HDL2            ●    ●  ●    ● 
aJuvenile and Westphal variants of HD 
bTypically SCA2 
cTypically SCA17 
Investigations 
Onset?
Confirm presence of 
chorea
Acute or subacute Chronic
Family history?
Present
Directed clinical 
tests
Directed genetic 
tests*
Clinical and genetic 
tests* in parallel
Directed genetic 
tests*
Absent
If negative
Directed clinical 
tests
If negative
 
Figure 2. Approach to investigation of the patient with chorea. *Genetic testing should 
always be accompanied by detailed genetic counselling. Wild/Tabrizi  16 
Investigation of chorea should be directed to the most likely causes (Figure 2). In acute or 
subacute onset chorea, the diagnosis is most likely to be made on the basis of blood tests 
and neuroimaging. In chronic or clearly familial cases, genetic testing may render extensive 
clinical  testing  unnecessary.  In  some  cases,  both  approaches  may  need  to  be  pursued 
simultaneously.  Genetic  testing  of  any  patient  should  always  be  preceded  by  genetic 
counselling. 
Table 6. Clinical tests to consider in chorea 
Test  Notes 
MRI imaging   Stroke or other focal basal ganglia pathology 
 T2* imaging abnormal in iron accumulation 
disorders 
 FLAIR imaging abnormal in prion disease 
 Deep brain T2 hyperintensities in Wilson’s disease 
Full blood count   Haematocrit may be elevated in PRV 
Red cell mass   Sensitive test required for diagnosis of PRV 
Blood film   Multiple films necessary to exclude 
neuroacanthocytosis 
Serum caeruloplasmin   Reduced in Wilson’s disease 
Urinary copper level   Elevated in Wilson’s disease 
Liver biopsy   Sometimes required to diagnose Wilson’s disease 
Pregnancy test   Chorea gravidarum in first trimester 
HIV test   Chorea may be presenting feature of AIDS 
Erythrocyte  sedimentation  rate  and 
antinuclear antibody 
 Sensitive tests to reveal SLE 
Anti-dsDNA   Relatively specific to SLE 
Anticardiolipin and lupus anticoagulant   Antiphospholipid syndrome is risk factor for chorea  
Thyroid function tests   Thyrotoxicosis 
Anti-streptolysin O titre   Recent streptococcal infection suggests 
Sydenham’s chorea/PANDAS 
Antibasal ganglia antibodies   Associated with post-infective chorea, chorea 
gravidarum and OCP-induced chorea 
Muscle biopsy   Ragged red fibres or respiratory chain 
abnormalities in mitochondrial disease 
Cerebrospinal fluid analysis   May reveal inflammatory/neoplastic causes 
Genetic testing and counselling 
We suggest a structured, sequential approach to genetic testing based on clinical findings 
(Figure 3). The identification of a new genetic diagnosis has widespread ramifications for the 
patient and their family members. A positive diagnostic genetic test for HD in a person with 
no known family history immediately means that all their siblings and children are at 50% risk 
of the disease. Genetic testing for any disease has the potential to cause significant distress Wild/Tabrizi  17 
and should not be performed without detailed genetic counselling. Most clinicians are aware 
of the need for counselling of at-risk individuals for predictive testing, but the fact that a 
patient is symptomatic does not remove the need to provide detailed counselling, time for 
reflection and support during and after delivery of the result. There are internationally agreed 
guidelines for testing of at-risk individuals in HD, which is always performed in a specialist 
genetics setting.
40 We summarise guidelines for diagnostic genetic testing in Table 7, to 
highlight that, when correctly conducted, the process of genetic counselling requires time, 
support and expertise that may not be available in the busy general neurology clinic. We 
therefore  recommend  if  possible  that  genetic  testing  be  performed  through  specialist 
neurogenetics services and supported by lay organisations.
40 
Table 7. Recommended guidelines for  diagnostic  genetic testing for HD and other 
autosomal  dominant  neurodegenerative  disorders.  Predictive  testing  in  HD  is  only 
undertaken in specialist genetic centres.  
  Principles of genetic counselling and testing 
o  Testing for HD should not be part of a routine blood investigation for chorea 
o  Patient  should  be  encouraged  to  select  a  companion  to  accompany  him  or  her 
throughout the testing process.  
o  The patient and their family need to be aware of the implications for them of a positive 
genetic result 
o  A follow-up protocol should be agreed 
o  Strict confidentiality must be observed 
o  Informed consent signed by neurologist and patient 
  Arrangements for counselling and testing  
o  The patient should be given the result with their chosen companion and not alone 
o  Result should be delivered as soon as possible after completion of the test, on an 
agreed date  
o  The patient has the right to decide not to receive the result or not to be genetically 
tested.  
o  A rapid follow-up appointment (within one month) should be arranged after delivery of 
a positive genetic result 
  Information to be given to the patient 
o  Clinical manifestations of HD, social and psychological implications, genetic aspects, 
reproductive implications, availability of treatment, and so forth 
o  Support and information from lay organisations 
o  How test is done 
o  Test cannot predict symptoms, severity or rate of progression 
o  Consequences for the patient, spouse/partner, children and other family members 
o  Socioeconomic consequences (employment, insurance, social security, data security 
and others) 
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Figure 3. Suggested approach to initial genetic testing in chorea. 
Pharmacological management of chorea 
Chorea may cause cosmetic embarrassment or disability, but many patients do not notice 
the severity of their chorea. Indeed, it is often relatives who request treatment. Anti-choreic 
medication should be used sparingly as no drug is particularly efficacious, and motor side-
effects  may  worsen  functional  disability.  Treatment  of  underlying  causes,  cognitive  and 
psychiatric  features  is  more  important  than  symptomatic  management  of  chorea.  For 
functionally disabling chorea, sulpiride, olanzapine and risperidone at low doses are useful. 
Tetrabenazine is a good option, but may cause sedation and depression.
12 
Practice points 
o  Chorea  may  vary  in  severity  from  subtle  finger-flicking  to  continuous,  violent 
movements and may overlap with other movement disorders  
o  A cause is identified in most cases of chorea Wild/Tabrizi  19 
o  A detailed history and examination will usually reveal associated features that may 
suggest a diagnosis and direct investigation 
o  Genetic  and  acquired  causes  should  be  considered  and  tested for  systematically 
depending on the clinical course and family history 
o  Huntington’s disease is by far the commonest genetic cause of chorea 
o  Genetic testing for any condition, even in symptomatic patients, should be preceded 
by  detailed,  expert  counselling  that  is  ideally  best  provided  by  a  specialist 
neurogenetics service 
Web links 
o  Huntington’s Disease Association (www.hda.org.uk) 
o  UK Huntington’s Disease Network (www.ukhdn.net) 
o  GeneTests medical genetics information (www.geneclinics.org) 
References 
 
1.  Krack P. Relicts of dancing mania: The dancing procession of Echternach. Neurology 
1999;53(9):2169-72. 
2.  The Huntington’s Disease Collaborative Research Group. A novel gene containing a 
trinucleotide  repeat  that  is  expanded  and  unstable  on  Huntington’s  disease 
chromosomes. Cell 1993;72(6):971-83. 
3.  Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, et al. 
Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington 
disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly 
individuals with 36-39 repeats. Am J Hum Genet 1996;59(1):16-22. Wild/Tabrizi  20 
4.  Kremer B, Almqvist E, Theilmann J, Spence N, Telenius H, Goldberg YP, et al. Sex-
dependent  mechanisms  for  expansions  and  contractions  of  the  CAG  repeat  on 
affected Huntington disease chromosomes. Am J Hum Genet 1995;57(2):343-50. 
5.  Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat 
length and clinical progression in Huntington’s disease. Neurology 1996;46(2):527-
31. 
6.  Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for 
prediction of the age of onset and penetrance for Huntington’s disease based on 
CAG length. Clinical Genetics 2004;65(4):267-277. 
7.  Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dode C, et al. A genome 
scan for modifiers of age at onset in Huntington disease: The HD MAPS study. Am J 
Hum Genet 2003;73(3):682-7. 
8.  Kremer  B.  Clinical  neurology  of  Huntington’s  disease.  In:  Harper  PS,  editor. 
Huntington’s disease. Oxford: Oxford Medical Publications, 2002. 
9.  Lasker AG, Zee DS. Ocular motor abnormalities in Huntington’s disease. Vision Res 
1997;37(24):3639-45. 
10.  Craufurd  D,  Snowden  J.  Neuropsychological  and  neuropsychiatric  aspects  of 
Huntington’s disease.  In: Harper  PS, editor. Huntington’s disease. Oxford:  Oxford 
Medical Publications, 2002. 
11.  Farrer  LA.  Suicide  and  attempted  suicide  in  Huntington  disease:  implications  for 
preclinical testing of persons at risk. Am J Med Genet 1986;24(2):305-11. 
12.  Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington’s 
disease since 1990. Expert Opin Pharmacother 2007;8(2):141-53. 
13.  Stevanin  G,  Fujigasaki  H,  Lebre  A-S,  Camuzat  A,  Jeannequin  C,  Dode  C,  et  al. 
Huntington’s disease-like phenotype due to trinucleotide repeat expansions in the 
TBP and JPH3 genes. Brain 2003;126(7):1599-1603. Wild/Tabrizi  21 
14.  Margolis  RL,  Holmes  SE,  Rosenblatt  A,  Gourley  L,  O’Hearn  E,  Ross  CA,  et  al. 
Huntington’s disease-like 2 (HDL2) in North America and Japan. Annals of Neurology 
2004;56(5):670-674. 
15.  Schols L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar 
ataxias:  clinical  features,  genetics,  and  pathogenesis.  The  Lancet  Neurology 
2004;3(5):291-304. 
16.  Machado  A,  Chien  HF,  Deguti  MM,  Cancado  E,  Azevedo  RS,  Scaff  M,  et  al. 
Neurological manifestations in Wilson’s disease: Report of 119 cases. Mov Disord 
2006;21(12):2192-6. 
17.  Caer M, Viala K, Levy R, Maisonobe T, Chochon F, Lombes A, et al. Adult-onset 
chorea and mitochondrial cytopathy. Mov Disord 2005;20(4):490-2. 
18.  Chinnery PF, Crompton DE, Birchall D, Jackson MJ, Coulthard A, Lombes A, et al. 
Clinical  features  and  natural  history  of  neuroferritinopathy  caused  by  the  FTL1 
460InsA mutation. Brain 2007;130(Pt 1):110-9. 
19.  Hartig  MB,  Hortnagel  K,  Garavaglia  B,  Zorzi  G,  Kmiec  T,  Klopstock  T,  et  al. 
Genotypic  and  phenotypic  spectrum  of  PANK2  mutations  in  patients  with 
neurodegeneration with brain iron accumulation. Ann Neurol 2006;59(2):248-56. 
20.  Ueno S, Maruki Y, Nakamura M, Tomemori Y, Kamae K, Tanabe H, et al. The gene 
encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. 
Nat Genet 2001;28(2):121-2. 
21.  Danek  A,  Walker  RH.  Neuroacanthocytosis.  Current  Opinion  in  Neurology 
2005;18(4):386-92. 
22.  Breedveld GJ, Percy AK, MacDonald ME, de Vries BB, Yapijakis C, Dure LS, et al. 
Clinical  and  genetic  heterogeneity  in  benign  hereditary  chorea.  Neurology 
2002;59(4):579-84. 
23.  Schrag A, Quinn NP, Bhatia KP, Marsden CD. Benign hereditary chorea—entity or 
syndrome? Mov Disord 2000;15(2):280-8. Wild/Tabrizi  22 
24.  Hanna  MG,  Davis  MB,  Sweeney  MG,  Noursadeghi  M,  Ellis  CJ,  Elliot  P,  et  al. 
Generalized  chorea  in  two  patients  harboring  the  Friedreich’s  ataxia  gene 
trinucleotide repeat expansion. Mov Disord 1998;13(2):339-40. 
25.  Piccolo I, Defanti CA, Soliveri P, Volontè MA, Cislaghi G, Girotti F. Cause and course 
in a series of patients with sporadic chorea. Journal of Neurology 2003;250(4):429-
435. 
26.  Cardoso  F,  Silva  CEAP,  Mota  CCC.  Chorea  in  fifty  consecutive  patients  with 
rheumatic fever. Movement Disorders 1997;12(5):701-703. 
27.  Ghika-Schmid  F,  Ghika  J,  Regli  F,  Bogousslavsky  J.  Hyperkinetic  movement 
disorders during and after acute stroke: The Lausanne Stroke Registry. Journal of 
the Neurological Sciences 1997;146(2):109-116. 
28.  Church AJ, Cardoso F, Dale RC, Lees AJ, Thompson EJ, Giovannoni G. Anti-basal 
ganglia  antibodies  in  acute  and  persistent  Sydenham’s  chorea.  Neurology 
2002;59(2):227-31. 
29.  Cardoso F, Maia D, César M, Cunningham QS, Valença G. Treatment of Sydenham 
chorea with corticosteroids. Movement Disorders 2003;18(11):1374-1377. 
30.  Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, et al. 
Therapeutic  plasma  exchange  and  intravenous  immunoglobulin  for  obsessive-
compulsive  disorder  and  tic  disorders  in  childhood.  The  Lancet 
1999;354(9185):1153-1158. 
31.  Marschitz I, Rodl S, Gruber-Sedlmayr U, Church A, Giovannoni G, Zobel G, et al. 
Severe chorea with positive anti-basal ganglia antibodies after herpes encephalitis. J 
Neurol Neurosurg Psychiatry 2007;78(1):105-107. 
32.  Jain  KK.  Drug-induced movement  disorders.  Drug-induced  neurological  disorders. 
Seattle: Hogrefe & Huber, 1996. 
33.  Miranda M, Cardoso F, Giovannoni G, Church A. Oral contraceptive induced chorea: 
another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg 
Psychiatry 2004;75(2):327-328. Wild/Tabrizi  23 
34.  Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea in 
the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics 
of  50  patients  from  our  clinics  and  the  recent  literature.  Medicine  (Baltimore) 
1997;76(3):203-12. 
35.  Isaacs  JD,  Rakshi  J,  Baker  R,  Brooks  DJ, Warrens  AN.  Chorea  associated  with 
thyroxine replacement therapy. Mov Disord 2005;20(12):1656-7. 
36.  Tse W, Cersosimo MG, Gracies JM, Morgello S, Olanow CW, Koller W. Movement 
disorders and AIDS: a review. Parkinsonism Relat Disord 2004;10(6):323-34. 
37.  Dike GL. Chorea gravidarum: a case report and review. Md Med J 1997;46(8):436-9. 
38.  Nazabal ER, Lopez JM, Perez PA, Del Corral PR. Chorea disclosing deterioration of 
polycythaemia vera. Postgrad Med J 2000;76(900):658-659. 
39.  Cao M, Olsen RJ, Zu Y. Polycythemia vera: new clinicopathologic perspectives. Arch 
Pathol Lab Med 2006;130(8):1126-32. 
40.  International Huntington Association and World Federation of Neurology Research 
Group on Huntington’s Chorea. Guidelines for the molecular genetics predictive test 
in Huntington’s disease. Neurology 1994;44(8):1533-6. 
 
 